GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VivoSim Labs Inc (LTS:0R02) » Definitions » EV-to-EBITDA

VivoSim Labs (LTS:0R02) EV-to-EBITDA : -0.25 (As of Jun. 01, 2025)


View and export this data going back to 2014. Start your Free Trial

What is VivoSim Labs EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, VivoSim Labs's enterprise value is $3.14 Mil. VivoSim Labs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-12.62 Mil. Therefore, VivoSim Labs's EV-to-EBITDA for today is -0.25.

The historical rank and industry rank for VivoSim Labs's EV-to-EBITDA or its related term are showing as below:

LTS:0R02' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.32   Med: -1.72   Max: 0.98
Current: -0.25

During the past 13 years, the highest EV-to-EBITDA of VivoSim Labs was 0.98. The lowest was -13.32. And the median was -1.72.

LTS:0R02's EV-to-EBITDA is ranked worse than
100% of 493 companies
in the Biotechnology industry
Industry Median: 8.65 vs LTS:0R02: -0.25

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-01), VivoSim Labs's stock price is $3.174. VivoSim Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-10.200. Therefore, VivoSim Labs's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


VivoSim Labs EV-to-EBITDA Historical Data

The historical data trend for VivoSim Labs's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VivoSim Labs EV-to-EBITDA Chart

VivoSim Labs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.29 -2.76 -0.55 -0.28 -0.60

VivoSim Labs Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.60 -0.42 -0.46 -0.62

Competitive Comparison of VivoSim Labs's EV-to-EBITDA

For the Biotechnology subindustry, VivoSim Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's EV-to-EBITDA falls into.


;
;

VivoSim Labs EV-to-EBITDA Calculation

VivoSim Labs's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3.139/-12.622
=-0.25

VivoSim Labs's current Enterprise Value is $3.14 Mil.
VivoSim Labs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VivoSim Labs  (LTS:0R02) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

VivoSim Labs's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.174/-10.200
=At Loss

VivoSim Labs's share price for today is $3.174.
VivoSim Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.200.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


VivoSim Labs EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of VivoSim Labs's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


VivoSim Labs Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.

VivoSim Labs Headlines

No Headlines